Is it possible to decrease the rate of Staphylococcus aureus peritonitis?
Piraino
B
B
D000279:Administration, Cutaneous; D000281:Administration, Intranasal; D000284:Administration, Oral; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000627:therapeutic use; D002404:Catheterization / Q000009:adverse effects / Q000295:instrumentation; D006801:Humans; D016712:Mupirocin / Q000008:administration & dosage / Q000627:therapeutic use; D009666:Nose / Q000382:microbiology; D009824:Ointments; D010530:Peritoneal Dialysis / Q000009:adverse effects* / Q000295:instrumentation; D010531:Peritoneal Dialysis, Continuous Ambulatory / Q000009:adverse effects* / Q000295:instrumentation; D010538:Peritonitis / Q000382:microbiology* / Q000517:prevention & control; D012293:Rifampin / Q000008:administration & dosage / Q000627:therapeutic use; D012307:Risk Factors; D013203:Staphylococcal Infections / Q000517:prevention & control*; D013211:Staphylococcus aureus / Q000187:drug effects
D000900:Anti-Bacterial Agents; D009824:Ointments; D016712:Mupirocin; D012293:Rifampin